María  Adelaida García-Gimeno

Dr. María Adelaida García-Gimeno

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2004 in Diabetes
Verified
Journal Article
Closed access
PDF file
ACAntonio L. Cuesta-Muñoz
Antonio L. Cuesta-Muñoz
HHHanna Huopio
Hanna Huopio
TOTimo Otonkoski
Timo Otonkoski
JGJuan M. Gomez-Zumaquero
Juan M. Gomez-Zumaquero
KNKirsti Näntö-Salonen
Kirsti Näntö-Salonen
MLMarkku Laakso
Markku Laakso
Glucokinase (GK) is a glycolytic key enzyme that functions as a glucose sensor in the pancreatic β-cell, where it governs glucose-stimulated insulin secretion (GSIS). Heterozygous inactivating mutations in the glucokinase gene (GCK) cause a mild form of diabetes (maturity-onset diabetes of the young [MODY]2), and activating mutations have been associated with a mild form of familial hyperinsulinemic hypoglycemia. We describe the first case of severe persistent hyperinsulinemic hypoglycemia due to a “de novo” mutation in GCK (Y214C). A baby girl presented with hypoglycemic seizures since the first postnatal day as well as with inappropriate hyperinsulinemia. Severe hypoglycemia persisted even after treatment with diazoxide and subtotal pancreatectomy, leading to irreversible brain damage. Pancreatic histology revealed abnormally large and hyperfunctional islets. The mutation is located in the putative allosteric activator domain of the protein. Functional studies of purified recombinant glutathionyl S-transferase fusion protein of GK-Y214C showed a sixfold increase in its affinity for glucose, a lowered cooperativity, and increased kcat. The relative activity index of GK-Y214C was 130, and the threshold for GSIS predicted by mathematical modeling was 0.8 mmol/l, compared with 5 mmol/l in the wild-type enzyme. In conclusion, we have identified a de novo GCK activating mutation that causes hyperinsulinemic hypoglycemia of exceptional severity. These findings demonstrate that the range of the clinical phenotype caused by GCK mutations varies from complete insulin deficiency to extreme hyperinsulinemia.

Verified
Journal Article
Open access
PDF file
PSPascual Sanz
Pascual Sanz
MGMaría Adelaida García-Gimeno
María Adelaida García-Gimeno
Neuroinflammation and epilepsy are interconnected. Brain inflammation promotes neuronal hyper-excitability and seizures, and dysregulation in the glia immune-inflammatory function is a common factor that predisposes or contributes to the generation of seizures. At the same time, acute seizures upregulate the production of pro-inflammatory cytokines in microglia and astrocytes, triggering a downstream cascade of inflammatory mediators. Therefore, epileptic seizures and inflammatory mediators form a vicious positive feedback loop, reinforcing each other. In this work, we have reviewed the main glial signaling pathways involved in neuroinflammation, how they are affected in epileptic conditions, and the therapeutic opportunities they offer to prevent these disorders.

16 June 2005 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
Pilar Gonzalez-CaboPilar Gonzalez-Cabo
Pilar Gonzalez-Cabo
RVRafael Vazquez-Manrique
Rafael Vazquez-Manrique
MGMaría Adelaida García-Gimeno
María Adelaida García-Gimeno
PSPascual Sanz
Pascual Sanz
FPFrancesc Palau
Francesc Palau
Frataxin deficiency is the main cause of Friedreich ataxia, an autosomal recessive neurodegenerative disorder. Frataxin function in mitochondria has not been fully explained yet. In this work, we show that Saccharomyces cerevisiae frataxin orthologue Yfh1p interacts physically with succinate dehydrogenase complex subunits Sdh1p and Sdh2p of the yeast mitochondrial electron transport chain and also with electron transfer flavoprotein complex ETFα and ETFβ subunits from the electron transfer flavoprotein complex. Genetic synthetic interaction experiments confirmed a functional relationship between YFH1 and succinate dehydrogenase genes SDH1 and SDH2. We also demonstrate a physical interaction between human frataxin and human succinate dehydrogenase complex subunits, suggesting also a key role of frataxin in the mitochondrial electron transport chain in humans. Consequently, we suggest a direct participation of the respiratory chain in the pathogenesis of the Friedreich ataxia, which we propose to be considered as an OXPHOS disease.

Verified
Journal Article
Open access
PDF file
PSPascual Sanz
Pascual Sanz
TRTeresa Rubio
Teresa Rubio
MGMaría Adelaida García-Gimeno
María Adelaida García-Gimeno
Neuroinflammation and epilepsy are different pathologies, but, in some cases, they are so closely related that the activation of one of the pathologies leads to the development of the other. In this work, we discuss the three main cell types involved in neuroinflammation, namely (i) reactive astrocytes, (ii) activated microglia, and infiltration of (iii) peripheral immune cells in the central nervous system. Then, we discuss how neuroinflammation and epilepsy are interconnected and describe the use of different repurposing drugs with anti-inflammatory properties that have been shown to have a beneficial effect in different epilepsy models. This review reinforces the idea that compounds designed to alleviate seizures need to target not only the neuroinflammation caused by reactive astrocytes and microglia but also the interaction of these cells with infiltrated peripheral immune cells.

8 April 2010 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
SKSameer Kassem
Sameer Kassem
SBSonal Bhandari
Sonal Bhandari
PRPablo Rodríguez-Bada
Pablo Rodríguez-Bada
RMRoja Motaghedi
Roja Motaghedi
MHMaayan Heyman
Maayan Heyman
ACAntonio Luis Cuesta-Muñoz
Antonio Luis Cuesta-Muñoz
Rare, naturally occurring gene mutations provide important insights into normal human physiology. We report on a young girl with severe neonatal hypoglycemia due to a novel glucokinase mutation (V91L). Her father had a similar clinical course, but neither his DNA nor his pancreatic tissue was available for study.

5 June 2019 in Experimental & Molecular Medicine
Verified
Journal Article
Open access
PDF file
ASAna Sanchis
Ana Sanchis
MGMaría Adelaida García-Gimeno
María Adelaida García-Gimeno
ACAntonio Cañada
Antonio Cañada
MSMaría Dolores Sequedo
María Dolores Sequedo
JMJosé María Millán
José María Millán
RVRafael Vazquez-Manrique
Rafael Vazquez-Manrique
Huntington disease is a neurodegenerative condition for which there is no cure to date. Activation of AMP-activated protein kinase has previously been shown to be beneficial in in vitro and in vivo models of Huntington’s disease. Moreover, a recent cross-sectional study demonstrated that treatment with metformin, a well-known activator of this enzyme, is associated with better cognitive scores in patients with this disease. We performed a preclinical study using metformin to treat phenotypes of the zQ175 mouse model of Huntington disease. We evaluated behavior (motor and neuropsychiatric function) and molecular phenotypes (aggregation of mutant huntingtin, levels of brain-derived neurotrophic factor, neuronal inflammation, etc.). We also used two models of polyglutamine toxicity in Caenorhabditis elegans to further explore potential mechanisms of metformin action. Our results provide strong evidence that metformin alleviates motor and neuropsychiatric phenotypes in zQ175 mice. Moreover, metformin intake reduces the number of nuclear aggregates of mutant huntingtin in the striatum. The expression of brain-derived neurotrophic factor, which is reduced in mutant animals, is partially restored in metformin-treated mice, and glial activation in mutant mice is reduced in metformin-treated animals. In addition, using worm models of polyglutamine toxicity, we demonstrate that metformin reduces polyglutamine aggregates and restores neuronal function through mechanisms involving AMP-activated protein kinase and lysosomal function. Our data indicate that metformin alleviates the progression of the disease and further supports AMP-activated protein kinase as a druggable target against Huntington’s disease.